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B infection (HB infection¼ HBcAb positive, HBsAg negative)
and 138 patients with normal HB serology (control) who
were matched for age, time of auto-HCT, disease status and
preparative regimen. Both groups received HDC + auto-HCT
between 1989 and 2012. Primary endpoints were: 1) HB viral
reactivation: HBsAg positivity or 10-fold increase in HB viral
DNA; 2) hepatotoxicity, as deﬁned in NCI CTCv3.0.
Results: There were no signiﬁcant differences in immuno-
globulin subtype, bone marrow plasmacytosis, serum beta-2
microglobulin, albumin, creatinine or lactic dehydrogenase
(LDH) between the HB infection or the control group.
Approximately 70% in each group received melphalan alone
as preparative regimen. In the HB infection group, 52
patients (48%) were HBsAb-positive, and 23 (21%) had
detectable HB viral DNA prior to auto-HCT. Serum HB viral
DNA level was<100 IU/m in 22 patients, and<300 IU/ml in 1
patient. HB e antigen (HBeAg) was non-reactive in all 4
patients evaluated prior to auto-HCT. Only 1 patient with HB
infection received pre-emptive antiviral therapy with Lam-
ivudine, while 4 patients received Lamivudine (3) or
Tenofovir (1) at reactivation for a median duration of 1 year.
HB viral reactivation was seen in 6 of 108 (5.6%) in the HB
infection group vs. 0 of 138 in the control group (p¼0.006).
There was a >10-fold increase in HB viral DNA in 5 of 6
patients with HB viral reactivation, and in 2 of 5 HBeAg also
became reactive. Median time to HB reactivation from auto-
HCT was 2.6 years. NCI CTCv3.0 grade 1, 2, 3 or 4 increase in
alanine transferase, aspartate transferase, total bilirubin or
alkaline phosphatase was seen in 6, 1, 2 and 3 patients,
respectively in the HB infection group (9.3%) vs. 1, 2, 0 and
1 (2.9%) patients in the control group (p¼ 0.049). Only one
patient (0.9%) in the HB infection group vs. 6 (4.3%) in control
group died of non-relapse causes within 1-year of auto-HCT
(p¼0.13).With a median follow up of 30 and 28months in HB
infection vs. control groups, the median PFS was 21.4 and
18.7 months, respectively (p¼0.66). Median OS in HB
infection and control groups was 57.0 vs. 65.2 months,
respectively (p¼0.93).
Conclusion: Resolved HB infection is associated with a
signiﬁcant risk of HB viral reactivation and hepatotoxicity in
patients undergoing auto-HCT for MM. These complications
were reversible and were not associated with an increase in
TRM, PFS or OS.
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Background: Lenalidomide (LEN) in combination with stan-
dard-dose melphalan has shown signiﬁcant anti-multiplemyeloma (MM) activity. In this phase I/II trial we evaluated
the safety and efﬁcacy of combining escalating doses of LEN
and high-dose melphalan (HDM) for patients undergoing
autologous hematopoietic stem cell transplantation (auto-
HCT) for relapsed MM.
Methods: Doses were chosen adaptively for successive co-
horts of size 3 using an extension of the safety-efﬁcacy trade-
off design.Each cohort received melphalan 200 mg/m2plus
LEN at one of the four dose levels orally, for 7 days. Primary
endpoints were dose-limiting toxicity (DLT), deﬁned as
regimen-related death, graft failure, grade 3 or 4 atrial
ﬁbrillation, grade 4 deep venous thrombosis, or pulmonary
embolism occurring within 30 days post auto-HCT, and
efﬁcacy, deﬁned as complete response (CR) at day +90.
Results: 57 patients were enrolled between March 2010 and
April 2013. After safely escalating to 100 mg of LEN, patients
were adaptively randomized among the 4 LEN dose levels.
Three, 5, 24 and 25 patients were treated at 25, 50, 75 or 100
mg respectively. Median age at auto-HCT was 60 (34-72)
years, and median time from diagnosis to auto-HCT was 33
(5-214) months, with no signiﬁcant differences between the
4 dose levels. Sixteen (28%) patients had high-risk abnor-
malities on conventional cytogenetic or ﬂuorescent in-situ
hybridization (FISH) studies. Median prior lines of treatment
were 3 (1-11). Eighteen patients (32%) had a prior auto-HCT.
Twenty-four (42%) patients received post auto-HCT mainte-
nance. DLT was not seen at any of the 4 dose levels prior to
adaptive randomization. Grade 3-4 non-hematologic toxicity
was seen in 40 (70%) patients, with no signiﬁcant differences
between the 4 dose levels. Two patients died of nonrelapse
causes (viral infection 1, cardiac failure 1) with a TRM of 3%.
Median time to both neutrophil and platelet engraftment
was 11 days. At day 90, 7 (12%) patients achieved a CR, 30
(53%) achieved CR or very good partial response (VGPR), and
51 (89.5%) achieved CR, VGPR or partial response (PR), with
no signiﬁcant differences in response rates among the 4 LEN
dose levels. With a median follow up of 10.5 months (range
0.5-33.4), median progression-free (PFS) and overall survival
(OS) have not yet been reached. One and 2-year PFSwere 63%
and 59%, respectively. One and 2-year OS were 82% and 72%,
respectively. These compare favorably with our previous
experience of 2-year PFS and OS of 24% and 59%, respectively,
after salvage auto-HCT with melphalan alone. No second
primary malignancy (SPM) has been seen so far.
Conclusion: LEN up to 100 mg daily x 7 days can be safely
combined with high-dose melphalan for relapsed myeloma.
The regimen is associated with a high overall response rate
and 2 year PFS and OS of 59% and 72% in relapsed and heavily
pretreated patients, with no SPM so far.
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Treatment of AL amyloidosis with high dose intravenous
melphalan and autologous stem cell transplant (HDM/SCT) is
effective in inducing hematologic and clinical remissions
associated with prolonged survival. We have performed 607
transplants from July 1994 to August 2013 in the Amyloidosis
Center at Boston Medical Center. Patients were enrolled in
several sequential IRBeapproved protocols.
Figure 1. Overall survival based on achievement of hematologic CR
Abstracts / Biol Blood Marrow Transplant 20 (2014) S45eS56S48The median age of patients was 57 years (range, 28-80).
Treatment-related mortality (TRM), deﬁned as death occur-
ring within 100 days of SCT, was 9% (n¼52/607). Additionally,
there were 11 deaths during stem cell mobilization and
collection (SCMC). No death has occurred since 2005 during
SCMC and TRM has improved to 5% (n¼12/249). Total of 334
patients (55%) received melphalan at 200 mg/m2 and 273
(45%) received melphalan at 100-140 mg/m2 per protocol,
based upon age and organ function. Hematologic CR, as
deﬁned by international consensus criteria, occurred in 40%
(n¼204/512) of evaluable patients measured at 6-12 months
post SCT; by intention-to-treat the CR rate was 34%. Hema-
tologic CR occurred in 45% (n¼131/294) of patients who
received 200 mg/m2 of HDM compared to 33% (n¼73/218) of
patients who received 100-140 mg/m2 of HDM (X2 p¼0.02).
Hematologic relapse occurred in 40 patients (20%) with CR at
a median of 4 years (range, 1.6-12.4). The median OS is
6.7 years with a median follow-up of 4.5 years. The median
OS has not been reached for patients achieving a CR but
exceeds 12.8 years, compared to 6.0 years for those not
achieving CR (log-rank p<0.001). The median OS for patients
following hematologic relapse is 3.5 years. Twenty-ﬁve % of
patients are alive, up to 19 years after undergoing HDM/SCT.
These data highlight the remarkable long-term survival
obtained with HDM/SCT in AL amyloidosis. While survival is
strongly dependent upon achieving a hematologic CR, the
survival of patients who do not achieve a CR and of those
who relapse after CR also is notable, suggesting a beneﬁt of
treatment. Strategies to improve risk-stratiﬁcation of pa-
tients and reduce TRM, as well as using sequential or
combination therapies to increase the CR rate, will likely
improve outcomes in the future for patients who just a few
years ago were considered to have a rapidly fatal diagnosis.CLINICAL CELLULAR THERAPY41
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We have previously shown that small numbers of ex vivo-
expanded trivirus-speciﬁc T-cells (tVSTs) targeting EBV,
CMV, and Adv are safe, effective and protective in vivo.
However, broader implementation is limited by a
manufacturing process that is prolonged (8-12wks), complex
and requires infectious virus (EBV) and vector (Adv). More-
over, antigenic competition limits extension to additional
viruses. We have now made T-cell lines with activity against
5 common post-transplant viruses (EBV, CMV, Adv, BK,
HHV6), using a simpliﬁed 10-day procedure that excludes
viral components, and show that a single line can be clini-
cally effective against multiple viruses. With NHLBI-PACT
support 45 clinical-grade pentavalent (p)VSTs have been
generated. By exposing 30x106 PBMCs to overlapping
peptide libraries spanning Adv (Hexon, Penton), CMV (pp65,
IE1), EBV (LMP2, EBNA1, BZLF1), BK (Large T, VP1) and HHV6
(U11, U14, U90) antigens we expanded a median of 345x106
cells (range 99-825x106) over 9-11 days. The lines were
polyclonal, comprising both CD4+ (585%) and CD8+
(345%) cells, that expressed activation and memory
markers. pVST speciﬁcitywas dependent on the donor’s prior
viral exposure; 42/45 lines had Adv activity (Hexon:
453159; Penton: 367199 SFC/2x105), 24/45 against CMV
(IE1: 315135; pp65: 969442), 34/45 against EBV (LMP2:
14578; EBNA1: 11546; BZLF1: 10678), 24/45 against BK
(Large T: 13965; VP1: 22393) and 26/45 against HHV6
(U90: 11482; U11: 3817; U14: 9027). None of the lines
reacted against recipient cells. To date 11 allogeneic HSCT
recipients have received 0.5-2x107 pVSTs/m2 without
adverse events. Three patients received the cells prophylac-
tically and remained infection free up to 3 months post-
pVSTs. The other 8 patients were treated for one or more
active infections. Based on viral load measurements a single
infusion successfully controlled active infections associated
with all our targeted viruses: CMV (2 CR, 1 PR); EBV (4 CR,
including a frank PTLD case); Adv (1 CR); HHV6 (2 CR) and BK
(4 CR, 1 PR, 1 NR). Of note, all 3 patients with BK hemorrhagic
cystitis had marked improvement/disappearance of hema-
turia post-pVSTs. One subject had transient but severe
bladder pain with inﬂammation, seen on cytoscopy, and a
6-log fall in urine BK viral load with detection of BK-speciﬁc
T-cells in his bladder. Our only partially non-responding
patient had 3 viral infections (EBV, HHV6, BK) and cleared
EBV and HHV6 but not BK following the infusion of a line that
lacked speciﬁcity for this virus, likely reﬂecting the sero-
negative status of the donor. Thus, infusion of pVSTs has been
safe and clinically effective against up to four simultaneous/
sequential infections in a single HSCT recipient. We are
currently extending this platform to include other clinically
relevant viruses and are planning to assess the activity of “off
the shelf” 3rd party pVSTs for broader implementation.
